Emerald Advisers LLC Sells 30,741 Shares of LivaNova PLC $LIVN

Emerald Advisers LLC lowered its stake in LivaNova PLC (NASDAQ:LIVN) by 4.4% during the first quarter, Holdings Channel reports. The institutional investor owned 670,207 shares of the company’s stock after selling 30,741 shares during the period. LivaNova comprises approximately 1.3% of Emerald Advisers LLC’s investment portfolio, making the stock its 15th biggest position. Emerald Advisers LLC’s holdings in LivaNova were worth $42,598,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of LIVN. Millennium Management LLC raised its holdings in LivaNova by 17.3% in the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after acquiring an additional 514,268 shares during the period. Wellington Management Group LLP boosted its holdings in shares of LivaNova by 83.5% during the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after acquiring an additional 1,067,349 shares during the period. Vanguard Group Inc. boosted its holdings in shares of LivaNova by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after acquiring an additional 34,812 shares during the period. AQR Capital Management LLC grew its position in shares of LivaNova by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after purchasing an additional 496,165 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of LivaNova by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,787,928 shares of the company’s stock valued at $110,014,000 after purchasing an additional 66,755 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on LIVN shares. Mizuho lifted their price target on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Barclays upped their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. KeyCorp increased their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Finally, Robert W. Baird dropped their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $80.75.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by company insiders.

LivaNova Stock Performance

Shares of NASDAQ:LIVN opened at $82.98 on Tuesday. LivaNova PLC has a 12-month low of $41.01 and a 12-month high of $85.27. The company’s 50 day moving average price is $76.45 and its two-hundred day moving average price is $68.50. The firm has a market cap of $4.56 billion, a PE ratio of 42.55 and a beta of 0.86. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities research analysts predict that LivaNova PLC will post 3.73 earnings per share for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.